Language selection

Search

Details for: OPDIVO

Company: BRISTOL-MYERS SQUIBB CANADA

DIN DIN name Active Ingredient(s) Strength Dosage Form Route of Administration
02446626OPDIVONIVOLUMAB10 MG / MLSOLUTIONINTRAVENOUS
02446634OPDIVONIVOLUMAB10 MG / MLSOLUTIONINTRAVENOUS
Search Reported Side Effects Report a Side Effect

Summary Reports

Summary Basis of Decision
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - Opdivo (nivolumab) and Yervoy (ipilimumab) used alone, or in combination - Assessing the potential risk of Hemophagocytic Lymphohistiocytosis (HLH)
Summary Safety Review - Opdivo (nivolumab) - Assessing the Potential Risks of Certain Blood Disorders, and Cytokine Release and Tumor Lysis Syndromes

Consumer Information

The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.

Date modified: